S

Suven Pharma

(NSE: SUVENPHAR)

SUVENPHAR

434.3

0.00 (0.00%)

Suven Pharma Price Chart

Note: The data used to display charts is delayed by 15 mins as per guidelines.

Suven Pharma Price Chart

Note: The data used to display charts is delayed by 15 mins as per guidelines.

Suven Pharma Price Summary

Today’s High

452.85

Today’s Low

429.9

52 Week's High

452.85

52 Week's Low

429.9

Suven Pharma Fundamentals

Market Cap

14923.9 Cr

CASA

0.0

No. Of Shares

25.5 Cr

P/E

40.9

P/B

11.8

Face Value

1.0

Dividend Yeild

0.4

Book Value

41.8

Net Interest Income

26.8

Cost to Income

NA

Promoter Holdings

60.0

EPS

12.1

CAR

NA

ROE

33.4

ROCE

39.1

Profit Growth

NA

Suven Pharma Peer Comparison

COMPANY

PRICE

MCAP (cr)

P/B

P/E

EPS

ROE

ROCE

NII

Suven Pharma

434.3

14923.9 Cr

11.8

40.9

12.1

33.4

39.1

26.8

Ajanta Pharma

1269.35

15404.7 Cr

5.4

23.0

78.1

25.3

34.0

3.5

Natco Pharma

622.95

14331.5 Cr

3.7

48.7

17.0

7.8

9.5

562.0

Narayana Hrudayalaya

700.8

14165.3 Cr

7.6

0.0

-3.8

-7.0

-4.8

118.3

Sanofi India

5903.45

15991.2 Cr

8.4

19.2

410.6

44.6

58.0

631.0

JBCPL

1851.5

13149.2 Cr

5.4

21.7

57.9

27.5

36.3

141.2

FAQ’s on Suven Pharma

About Suven Pharma

Suven Pharmaceuticals Limited, a company incorporated in November 2018, has become Wholly Owned Subsidiary of Suven Life Sciences Limited, effective February 2019. Suven Life Sciences Limited, post the Board meeting on February 5, 2019, announced demerger of Suven Life Sciences Limited into: Suven Life Sciences Limited, the demerged entity, to continue innovative research focused on Central Nervous System (CNS) disorders to meet huge unmet global medical needs. Suven Pharmaceuticals Limited, the resultant entity, to continue the CRAMS business operations. The Scheme of Arrangement has since been approved by the National Company Law Tribunal (NCT), Hyderabad bench vide its order on 6th January 2020.

Pursuant to the Scheme of Arrangement between Suven Life Sciences Limited (‘Demerged Company’), Suven Pharmaceuticals Limited (‘Resulting Company’) and their respective shareholders and creditors, duly approved by the National Company Law Tribunal (NCLT), Hyderabad Bench, vide its Order dated 06th January, 2020, the Demerged Undertaking (as defined in the Scheme) of the Demerged Company has been demerged from Suven Life Sciences Limited and the same has been transferred to and vested in Suven Pharmaceuticals Limited with effect from 1st October, 2018, being the Appointed Date fixed in the said Scheme of Arrangement.

The Scheme, has become operative from the Appointed Date i.e., 1st October, 2018, but has become effective on 9th January, 2020 being the date on which certified copies of the Order of the NCLT, Hyderabad Bench sanctioning the Scheme was filed with the Registrar of Companies, Hyderabad, Telangana, both by the Demerged Company and Resulting Company.

Business area of the company

The company is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.

Business segments

  • Pharmaceutical Solutions
  • Active Pharma ingredients
  • Intermediates
  • Formulations

Trade Suven Pharma today

Create a free portfolio in Trinkerr and earn and grow along with peers